다시드림 vs ANRISK®
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
다시드림
Read full descriptionHide full description
환자분들이 특정 약제의 환급금을 보다 편리하게 신청 할 수 있도록 하기위한 공익적인 목적을 가지고 있는 앱 입니다. ‘다시드림(Dream) 은 환급금을 다시 드린 다는 의미와 함께 약물 치료를 통해 환자분들의 꿈(Dream) 도 이루시기를 바라는 의미를 가지고 있습니다. 이 어플은 특정 약제를 처방 받아 환급 안내를 받은 환자분들을 대상으로 하기 때문에 회원가입후 관리자의 검토와 승인을 거친 후 최종 가입 등록이 완료된 이후 환급 신청이 가능 하오니 참고 부탁 드립니다.
ANRISK®
Read full descriptionHide full description
"Brain aneurysm, the ticking time bomb in your head: Assess your risk solely based on screening results." Assess Your Brain Aneurysm Risk with ANRISK®—an AI Model Developed by Neurosurgeons. ■ Brain Aneurysms: Early Detection Is Key According to the Brain Aneurysm Foundation, a ruptured brain aneurysm has a fatality rate of 50%, but identifying risk factors early can significantly improve the risk level and prevent irreversible consequences. ■ Quick Analysis Using Basic Health Information ANRISK® is a non-generative AI model developed by a team of neurosurgery experts using 8.8 million person-years worth of data. It analyzes brain aneurysm risk based on 21 key variables such as age, sex, blood pressure, diabetes history, and smoking status. Users can receive a personalized risk score by entering basic health data—no additional tests are required. ■ Personalized Reports for Proactive Health Management Users receive an analysis report with a risk score and are categorized into one of five risk levels. The report also includes personalized health goals and lifestyle guidance to support proactive wellness and long-term risk awareness. ※ This app does not provide medical diagnosis or treatment. All health-related decisions should be made in consultation with a qualified professional. ■ ANRISK® Awards & Recognition *2023 Healthcare Big Data Startup Competition Grand Prize (Minister of Health and Welfare Award) - Rep. of Korea *CHALLENGE! K-Startup 2023 Innovation Startup League (General League) Grand Prize - Rep. of Korea *The 11th Pan Government Data Startup Competition Grand Prize (Presidential Award) - Rep. of Korea *LINA 50+ Awards (Creative Innovation) 1st place - Rep. of Korea ■ Important Disclaimer This app is designed to provide general health-related insights and should not be used for medical purposes. The information and risk scores provided are intended for personal awareness and wellness support only. They are not a substitute for professional medical advice, diagnosis, or treatment, and this app is not classified as a medical device. [Contact] hello@taloscorp.io
Screenshots
Verdict
The clearest difference is in-app purchases: 다시드림 at none against ANRISK®'s 3. On price, update cadence, ads and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. ANRISK® sells 3 one-off in-app purchases. 다시드림 asks for nothing beyond the download.
Both ship on a similar rhythm, roughly every 2 months. The most recent releases landed on October 25, 2026 and October 27, 2026 respectively.
| Parameter | 다시드림 | ANRISK® |
|---|---|---|
| Price | Free | Free |
| Update frequency | Every 2 months | Every 2 months |
| Ads | No | No |
| In-app purchases | No — better | Yes |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 15.1 | 15.1 |
| Further details — not scored | ||
| Size | 30 MB | 80 MB |
| Age rating | 4+ | 17+ |
| Developer | INNOBOOST | TALOS Corp. |
In-app purchases
다시드림
No in-app purchases
ANRISK®
- 1 ANRISK® Analysis Credit$19.99
- 5 ANRISK® Analysis Credits$99.99
- 10 ANRISK® Analysis Credits$199.99









